Publicacions en què col·labora amb Maurizio Bendandi (9)

2021

  1. Idiotype vaccines produced with a non-cytopathic alphavirus self-amplifying RNA vector induce antitumor responses in a murine model of B-cell lymphoma

    Scientific Reports, Vol. 11, Núm. 1

2017

  1. Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA)

    PLoS ONE, Vol. 12, Núm. 9

2016

  1. Identification of TIM3 2'-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy

    Oncotarget, Vol. 7, Núm. 4, pp. 4522-4530

  2. MRP1-CD28 bi-specific oligonucleotide aptamers: Target costimulation to drug-resistant melanoma cancer stem cells

    Oncotarget, Vol. 7, Núm. 17, pp. 23182-23196

  3. Targeting inhibition of Foxp3 by a CD28 2'-Fluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy

    Biomaterials, Vol. 91, pp. 73-80

2007

  1. Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer

    Expert Opinion on Biological Therapy, Vol. 7, Núm. 5, pp. 599-615

2006

  1. El potencial de la inmunomodulación con anticuerpos monoclonales anti-CD137 (4-1BB) para terapia de enfermedades malignas e infecciones viráles crónicas

    Anales del sistema sanitario de Navarra, Vol. 29, Núm. 1, pp. 77-96

  2. Immunogenic cell death and cross-priming are reaching the clinical immunotherapy arena

    Clinical Cancer Research

2005

  1. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas

    Journal of Clinical Oncology, Vol. 23, Núm. 5, pp. 999-1010